Active, Not Recruiting
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
NCT04164901
- Conditions
- Glioma, Grade 2 Glioma, Neoplasms, +8 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- City of Hope Duarte, California, United States
- University of California San Diego La Jolla, California, United States
- UCLA Oncology Center Los Angeles, California, United States